Patents by Inventor Vincent Mascitti

Vincent Mascitti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • (AZA)Benzothiazolyl Substituted Pyrazole Compounds
    Publication number: 20220184041
    Abstract: This application includes a compound of Formula I or a pharmaceutically acceptable salt thereof; wherein the variables R1a, R1b, R2, R3, X, Y and Z are as defined herein, pharmaceutical compositions comprising the compounds of Formula I and methods of treatment comprising administering to a patient in need thereof a compound of Formula I for the treatment of transthyretin amyloidosis and diseases related thereto.
    Type: Application
    Filed: November 23, 2021
    Publication date: June 16, 2022
    Applicant: Pfizer Inc.
    Inventors: Shawn Cabral, Daniel Paul Canterbury, Robert Lee Dow, Andrew Fensome, Magdalena Korczynska, Sophie Yvette Lavergne, Allyn Timothy Londregan, Vincent Mascitti, David Walter Piotrowski, Andre Shavnya, Meihua Mike Tu, Tao Wang, Hanna Maria Wisniewska
  • Tissue-specific genome engineering using CRISPR-Cas9
    Patent number: 10851367
    Abstract: The present application provides compounds, compositions, uses thereof for the treatment of diseases, conditions and/or disorders, and uses thereof as asialoglycoprotein receptor (ASGPR) targeting agents.
    Type: Grant
    Filed: November 9, 2016
    Date of Patent: December 1, 2020
    Assignees: Pfizer Inc., The Regents of the University of California
    Inventors: Spiros Liras, Vincent Mascitti, Benjamin Aaron Thuma, Jennifer A. Doudna, Romain Rouet
  • Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR
    Patent number: 10813942
    Abstract: Compounds of Formula (A) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by pharmaceutical compositions and the uses thereof as asialoglycoprotein receptor (ASGPR) targeting agents.
    Type: Grant
    Filed: June 24, 2019
    Date of Patent: October 27, 2020
    Assignee: Pfizer Inc.
    Inventors: Spiros Liras, Vincent Mascitti, Benjamin Thuma
  • SUBSTITUTED-6,8-DIOXABICYCLO[3.2.1]OCTANE-2,3-DIOL COMPOUNDS AS TARGETING AGENTS OF ASGPR
    Publication number: 20190321382
    Abstract: Compounds of Formula (A) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by pharmaceutical compositions and the uses thereof as asialoglycoprotein receptor (ASGPR) targeting agents.
    Type: Application
    Filed: June 24, 2019
    Publication date: October 24, 2019
    Applicant: Pfizer Inc.
    Inventors: Spiros Liras, Vincent Mascitti, Benjamin Thuma
  • Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR
    Patent number: 10376531
    Abstract: Compounds of Formula (A) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by pharmaceutical compositions and the uses thereof as asialoglycoprotein receptor (ASGPR) targeting agents.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: August 13, 2019
    Assignee: Pfizer Inc.
    Inventors: Spiros Liras, Vincent Mascitti, Benjamin Thuma
  • SUBSTITUTED-6,8-DIOXABICYCLO[3.2.1]OCTANE-2,3-DIOL COMPOUNDS AS TARGETING AGENTS OF ASGPR
    Publication number: 20180296585
    Abstract: Compounds of Formula (A) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by pharmaceutical compositions and the uses thereof as asialoglycoprotein receptor (ASGPR) targeting agents.
    Type: Application
    Filed: June 29, 2018
    Publication date: October 18, 2018
    Applicant: Pfizer Inc.
    Inventors: Spiros Liras, Vincent Mascitti, Benjamin Thuma
  • Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR
    Patent number: 10039778
    Abstract: Compounds of Formula (A) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by pharmaceutical compositions and the uses thereof as asialoglycoprotein receptor (ASGPR) targeting agents.
    Type: Grant
    Filed: February 16, 2017
    Date of Patent: August 7, 2018
    Assignee: Pfizer Inc.
    Inventors: Spiros Liras, Vincent Mascitti, Benjamin Thuma
  • SUBSTITUTED-6,8-DIOXABICYCLO[3.2.1]OCTANE-2,3-DIOL COMPOUNDS AS TARGETING AGENTS OF ASGPR
    Publication number: 20170165284
    Abstract: Compounds of Formula (A) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by pharmaceutical compositions and the uses thereof as asialoglycoprotein receptor (ASGPR) targeting agents.
    Type: Application
    Filed: February 16, 2017
    Publication date: June 15, 2017
    Applicant: Pfizer Inc.
    Inventors: Spiros Liras, Vincent Mascitti, Benjamin Thuma
  • TISSUE-SPECIFIC GENOME ENGINEERING USING CRISPR-CAS9
    Publication number: 20170137801
    Abstract: The present application provides compounds, compositions, uses thereof for the treatment of diseases, conditions and/or disorders, and uses thereof as asialoglycoprotein receptor (ASGPR) targeting agents.
    Type: Application
    Filed: November 9, 2016
    Publication date: May 18, 2017
    Inventors: Spiros Liras, Vincent Mascitti, Benjamin Aaron Thuma, Jennifer A. Doudna, Romain Rouet
  • Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR
    Patent number: 9617293
    Abstract: Compounds of Formula (A) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by pharmaceutical compositions and the uses thereof as asialoglycoprotein receptor (ASGPR) targeting agents.
    Type: Grant
    Filed: April 7, 2016
    Date of Patent: April 11, 2017
    Assignee: Pfizer Inc.
    Inventors: Spiros Liras, Vincent Mascitti, Benjamin Thuma
  • Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
    Patent number: 9439902
    Abstract: Compounds of Formula (A) and (B) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by sodium-glucose transporter inhibitors (in particular, SGLT2 inhibitors).
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: September 13, 2016
    Assignee: Pfizer Inc.
    Inventor: Vincent Mascitti
  • Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
    Patent number: 9439901
    Abstract: Compounds of Formula (A) and (B) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by sodium-glucose transporter inhibitors (in particular, SGLT2 inhibitors).
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: September 13, 2016
    Assignee: Pfizer Inc.
    Inventor: Vincent Mascitti
  • SUBSTITUTED-6,8-DIOXABICYCLO[3.2.1]OCTANE-2,3-DIOL COMPOUNDS AS TARGETING AGENTS OF ASGPR
    Publication number: 20160207953
    Abstract: Compounds of Formula (A) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by pharmaceutical compositions and the uses thereof as asialoglycoprotein receptor (ASGPR) targeting agents.
    Type: Application
    Filed: April 7, 2016
    Publication date: July 21, 2016
    Applicant: Pfizer Inc.
    Inventors: Spiros Liras, Vincent Mascitti, Benjamin Thuma
  • Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR
    Patent number: 9340553
    Abstract: Compounds of Formula (A) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by pharmaceutical compositions and the uses thereof as asialoglycoprotein receptor (ASGPR) targeting agents.
    Type: Grant
    Filed: May 18, 2015
    Date of Patent: May 17, 2016
    Assignee: Pfizer Inc.
    Inventors: Spiros Liras, Vincent Mascitti, Benjamin Thuma
  • Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
    Patent number: 9308204
    Abstract: Compounds of Formula (A) and (B) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by sodium-glucose transporter inhibitors (in particular, SGLT2 inhibitors).
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: April 12, 2016
    Assignee: Pfizer Inc.
    Inventor: Vincent Mascitti
  • SUBSTITUTED-6,8-DIOXABICYCLO[3.2.1]OCTANE-2,3-DIOL COMPOUNDS AS TARGETING AGENTS OF ASGPR
    Publication number: 20150329555
    Abstract: Compounds of Formula (A) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by pharmaceutical compositions and the uses thereof as asialoglycoprotein receptor (ASGPR) targeting agents.
    Type: Application
    Filed: May 18, 2015
    Publication date: November 19, 2015
    Applicant: PFIZER INC.
    Inventors: Spiros Liras, Vincent Mascitti, Benjamin Thuma
  • DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES
    Publication number: 20150065513
    Abstract: Compounds of Formula (A) and (B) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by sodium-glucose transporter inhibitors (in particular, SGLT2 inhibitors).
    Type: Application
    Filed: November 7, 2014
    Publication date: March 5, 2015
    Applicant: PFIZER INC.
    Inventor: Vincent Mascitti
  • DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES
    Publication number: 20150065565
    Abstract: Compounds of Formula (A) and (B) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by sodium-glucose transporter inhibitors (in particular, SGLT2 inhibitors).
    Type: Application
    Filed: November 7, 2014
    Publication date: March 5, 2015
    Applicant: Pfizer Inc.
    Inventor: Vincent Mascitti
  • DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES
    Publication number: 20150065512
    Abstract: Compounds of Formula (A) and (B) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by sodium-glucose transporter inhibitors (in particular, SGLT2 inhibitors).
    Type: Application
    Filed: November 7, 2014
    Publication date: March 5, 2015
    Applicant: Pfizer Inc.
    Inventor: Vincent Mascitti
  • Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
    Patent number: 8669380
    Abstract: Compounds of Formula (A) and (B) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by sodium-glucose transporter inhibitors (in particular, SGLT2 inhibitors).
    Type: Grant
    Filed: October 21, 2010
    Date of Patent: March 11, 2014
    Assignee: Pfizer Inc.
    Inventor: Vincent Mascitti